Evidence map›Paper›PMID 33438069›Full record

Observational studyCancer chemotherapy and pharmacology2021

Does bevacizumab increase joint pain in patients with cancer? Results of the prospective observational BEVARTHRALGIA study.

Enora Vauléon, Hélène Behal, Loïc Lebellec, Renaud Desbarbieux, Simon Baldacci, Nicolas Simon, Diane Pannier, Marie-Hélène Vieillard, Anthony Turpin

Registry-linked trialAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Cancer chemotherapy and pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03455907 (Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03455907 completednot on this map

Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer

TypeobservationalSponsorUniversity Hospital, LilleRan2018 to 2019Enrolled71ConditionsArthralgia
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Observational
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Enora VauléonMedical Oncology Department, CHU Lille, University of Lille, Lille, France.
Hélène BehalULR 2694, METRICS: Évaluation des Technologies de santé et des Pratiques Médicales, University Lille, CHU Lille, Lille, France.
Loïc LebellecDepartment of Medical Oncology, Oscar Lambret Center, Lille, France.
Renaud DesbarbieuxHôpital Duchenne, Boulogne sur mer, France.
Simon BaldacciCNRS, Inserm, Institut Pasteur de Lille, UMR9020, UMR-S 1277, Canther, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Thoracic Oncology Department, CHU Lille, University of Lille, Lille, France.
Nicolas SimonULR 7365-GRITA-Groupe de Recherche Sur Les Formes Injectables et les Technologies Associées, University Lille, CHU Lille, 59000, Lille, France.
Diane PannierDepartment of Medical Oncology, Oscar Lambret Center, Lille, France.
Marie-Hélène Vieillard *Department of Medical Oncology, Oscar Lambret Center, Lille, France.
Anthony Turpin *CNRS, Inserm, Institut Pasteur de Lille, UMR9020, UMR-S 1277, Canther, Cancer Heterogeneity, Plasticity and Resistance To Therapies, Medical Oncology Department, University of Lille, CHU Lille, Lille, France. Anthony.turpin@chru-lille.fr.ORCID 0000-0002-2282-0101
Centre National de la Recherche Scientifique · FRCentre Hospitalier Universitaire de Lille · FRCentre Oscar Lambret · FRUniversité de Lille · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe occurrence of arthralgia and myalgia during treatment with bevacizumab (Bev) has been described but not spontaneously reported. We aimed to evaluate the frequency of arthralgia in patients treated with Bev and identify the risk factors.

methodsIn this observational prospective study, a self-administered questionnaire was distributed to patients at the initiation of Bev and at 3 and 6 months of treatment. Bev (5-15 mg/kg) was administered every 2 or 3 weeks, with or without chemotherapy.

resultsA total of 71 patients (42 with colorectal cancer, 22 with ovarian cancer, and 7 with lung cancer) were enrolled from January to November 2018. All patients completed the questionnaire at initiation, while only 56 (78.9%) and 36 (50.7%) patients completed the questionnaire at 3 and 6 months, respectively. The frequency of joint pain was 29.6% before Bev treatment and increased to 41.8% and 50% at 3 and 6 months, respectively, without reaching significance. The evolution of pain was significant according to the Common Terminology Criteria for Adverse Events grades (P = 0.032). No significant increase in the impact of pain on instrumental or elementary activities was observed over time. The frequency of arthralgia significantly increased at 3 months in patients with ovarian cancer versus those with colorectal cancer (odds ratio: 19.50; 95% confidence interval 4.53-83.98; P < 0.001).

conclusionsBev‑including regimens tend to be associated with a significant increase in the frequency of arthralgia in women treated for ovarian cancer. Physicians should be aware of this side effect. CLINICAL TRIAL NUMBER: NCT03455907, date of registration: March 7, 2018.

Indexed as

AdultAgedArthralgiaBevacizumabColorectal NeoplasmsFemaleHumansLung NeoplasmsMaleMiddle AgedNeoplasmsOvarian NeoplasmsProspective StudiesBevacizumabArthralgiaColorectal cancerLung cancerOvarian cancerTargeted therapy

Identifiers

PMID33438069
OpenAlexW3120883684

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.